Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $3,559,646.18. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $2.46 during mid-day trading on Friday, reaching $77.86. The company’s stock had a trading volume of 2,278,752 shares, compared to its average volume of 1,180,013. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $88.02. The stock has a fifty day moving average of $52.53 and a two-hundred day moving average of $42.56. The firm has a market capitalization of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Patient Square Capital LP bought a new position in Dianthus Therapeutics during the third quarter valued at $4,919,000. XTX Topco Ltd bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth about $503,000. Sio Capital Management LLC increased its holdings in shares of Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after buying an additional 119,073 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Dianthus Therapeutics by 13.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after buying an additional 196,117 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $2,504,000. 47.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DNTH. Wedbush upped their target price on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday. Oppenheimer lifted their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $63.00 to $123.00 in a research note on Tuesday. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday. Finally, Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $115.33.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.